Albumin/interferon alpha 2a fusion protein

重组人血清白蛋白/干扰素α2a融合蛋白

Report date: 2026/05/20 20:02:01

Base Information

Drug NameAlbumin/interferon alpha 2a fusion protein
Drug Alias NameRecombinant human serum albumin/interferon alpha2a fusion proteinSFR-9213rHSA-IFN alpha-2a
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesTianjin Puying Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Bio-Fortune LtdTianjin Linda Biotechnology Co LtdFortunerock (China) Ltd +[5] 
Active IndicationsN/A
Inactive IndicationsHepatitis B, Chronic

Other Information

ATC CodeN/A
Related LinksN/A